Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Yee

Showing results (151-160 of 188) with videos related to

Pageof 19
Sort By:
JCO Precision Oncology|September 11, 2020
Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIALJulia D Wulfkuhle, Christina Yau, Denise M Wolf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2024
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant ChemotherapyMark Jesus M Magbanua, Ziad Ahmed, Rosalyn W Sayaman, et al.
Bone|December 24, 2014
A phase I feasibility study of multi-modality imaging assessing rapid expansion of marrow fat and decreased bone mineral density in cancer patientsSusanta K Hui, Luke Arentsen, Thanasak Sueblinvong, et al.
Breast Cancer Research and Treatment|January 6, 2026
RISE UP for breast cancer 2024: conference highlights & takeawaysTaylor Glatt, Katherine Leggat-Barr, Nandini Seth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2013
Developing safety criteria for introducing new agents into neoadjuvant trialsAngela DeMichele, Donald A Berry, JoAnne Zujewski, et al.
Journal of Magnetic Resonance Imaging : JMRI|December 17, 2016
MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trialPatrick J Bolan, Eunhee Kim, Benjamin A Herman, et al.
The Journal of Pathology|May 15, 2023
Receptor for hyaluronan-mediated motility (RHAMM) defines an invasive niche associated with tumor progression and predicts poor outcomes in breast cancer patientsSarah E Tarullo, Yuyu He, Claire Daughters, et al.
Breast Cancer Research and Treatment|December 3, 2024
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancerHope S Rugo, Mike Campbell, Christina Yau, et al.
Nature Communications|March 20, 2026
Tumor-specific lncRNA IGF1R-AS1 trans-regulates chromatin interactions associated with oncogenic MYC signalingYongyong Yang, Ting-You Wang, Joshua Fry, et al.
Cell Reports. Medicine|November 7, 2024
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancerMichael J Campbell, Denise M Wolf, Christina Yau, et al.
Pageof 19

Showing results (151-160 of 188) with videos related to

Sort By:
Pageof 19
JCO Precision Oncology|September 11, 2020
Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIALJulia D Wulfkuhle, Christina Yau, Denise M Wolf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2024
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant ChemotherapyMark Jesus M Magbanua, Ziad Ahmed, Rosalyn W Sayaman, et al.
Bone|December 24, 2014
A phase I feasibility study of multi-modality imaging assessing rapid expansion of marrow fat and decreased bone mineral density in cancer patientsSusanta K Hui, Luke Arentsen, Thanasak Sueblinvong, et al.
Breast Cancer Research and Treatment|January 6, 2026
RISE UP for breast cancer 2024: conference highlights & takeawaysTaylor Glatt, Katherine Leggat-Barr, Nandini Seth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2013
Developing safety criteria for introducing new agents into neoadjuvant trialsAngela DeMichele, Donald A Berry, JoAnne Zujewski, et al.
Journal of Magnetic Resonance Imaging : JMRI|December 17, 2016
MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trialPatrick J Bolan, Eunhee Kim, Benjamin A Herman, et al.
The Journal of Pathology|May 15, 2023
Receptor for hyaluronan-mediated motility (RHAMM) defines an invasive niche associated with tumor progression and predicts poor outcomes in breast cancer patientsSarah E Tarullo, Yuyu He, Claire Daughters, et al.
Breast Cancer Research and Treatment|December 3, 2024
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancerHope S Rugo, Mike Campbell, Christina Yau, et al.
Nature Communications|March 20, 2026
Tumor-specific lncRNA IGF1R-AS1 trans-regulates chromatin interactions associated with oncogenic MYC signalingYongyong Yang, Ting-You Wang, Joshua Fry, et al.
Cell Reports. Medicine|November 7, 2024
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancerMichael J Campbell, Denise M Wolf, Christina Yau, et al.
Pageof 19